Last reviewed · How we verify

NCT05078541

Radiofrequency Ablation for Warthin's Tumor

Completed NA Last updated 8 February 2023
What this trial tests

NA trial testing Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor in Radiofrequency Ablation in 20 participants. Completed in 15 December 2022.

Timeline
20 October 2021
Primary endpoint
15 December 2022
15 December 2022

Quick facts

Lead sponsorChinese University of Hong Kong
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date20 October 2021
Primary completion15 December 2022
Estimated completion15 December 2022
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Radiofrequency Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a safety and feasibility study to determine if ultrasound guided radiofrequency ablation of parotid Warthin's tumor under local anesthesia is a safe and effective procedure compared to Parotidectomy while using less resources.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Radiofrequency Ablation

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05078541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing